Clonidine Oral Suspension (Onyda XR) for ADHD

The FDA has approved Onyda XR (Tris), an extended-release (ER) oral suspension formulation of the alpha2-adrenergic agonist clonidine, for use as monotherapy or as an adjunct to stimulant therapy for treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥6 years old. Clonidine ER tablets have been available for years for treatment of ADHD in children 6-17 years old.

Publication Details

Journal: The medical letter on drugs and therapeutics/The medical letter
Published: 2024-12-23
DOI: https://doi.org/10.58347/tml.2024.1718d
Primary Topic: Attention Deficit Hyperactivity Disorder
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clonidine Oral Suspension (Onyda XR) for ADHD

Dec 23, 2024

The medical letter on drugs and therapeutics/The medical letter

Attention Deficit Hyperactivity Disorder

article

Clonidine Oral Suspension (Onyda XR) for ADHD

December 23, 2024article en

Abstract

The medical letter on drugs and therapeutics/The medical letterVol. 66(1718)

Good health and well-being

Openalex Percentile: Top 65%

Attention Deficit Hyperactivity Disorder

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clonidine Oral Suspension (Onyda XR) for ADHD · The medical letter on drugs and therapeutics/The medical letter (2024) | TGRS Research Map | TGRS